Shire Plc: Feedback from a quick business update + Comments on potential Lialda generics

BUY-Top Picks, Fair Value  6900p (+35%)

News published on September Tuesday 20, 2016
Share on

Last Friday, the CFO provided a quick business update. Among the different issues that were addressed we note that 1/ M&A could be brought back to the table by next year; 2/ the integration of BXLT is going pretty fast. Apart from that, SHP announced that a court has ruled in favour of Cadilla/Zydus regarding the potential validity of its generic version of Lialda. While this is a negative per se, note that 1/Shire will obviously file an appeal… and previously won a court against another generic makers (Actavis); 2/ the impact on our FV would be quite limited (less than GBp100).


For more information, please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities